Immune Monitoring of Clinical Trials with Biotherapies

Advances in Clinical Chemistry

Volumn 45, Issue SUPPL.: COMPLETE, 2008, Pages 75-97

  Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANTIBODY PRODUCTION; CELLULAR IMMUNITY; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOTHERAPY; METHODOLOGY; MONITORING; QUALITY CONTROL; REVIEW;

ANTIBODY FORMATION; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MONITORING, PHYSIOLOGIC; QUALITY CONTROL;

EID: 38649143658     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(07)00004-2     Document Type: Review

References (37)

1. Haque A., and Blum J. New insights in antigen processing and epitope selection: Development of novel immunotherapic strategies for cancer, autoimmunity and infectious diseases. J Biol Regul Homeost Agents 19 3-4 (2005) 93-104
2. van Eden W. Immunoregulation of autoimmune disease. Hum Immunol 67 6 (2006) 446-453
3. Matzinger P. The danger model: A renewed sense of self. Science 296 (2002) 301-305
4. Sentman C., Barber M., Barber A., and Zhang T. NK cell receptors as tools in cancer immunotherapy. Adv Cancer Res 95 (2006) 249-292
5. Waldmann T. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 6 (2006) 595-601
6. Hinrichs C., Gattinoni L., and Restifo N. Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol 18 (2006) 363-370
7. Lotze M., Wang E., Marincola F., Hanna N., Bugelski P., Burns C., et al. Workshop on cancer biometrics: Identifying biomarkers and surrogates of cancer in patients: A meeting held at the Masur Auditorium, National Institutes of Health. J Immunother 28 (2005) 79-119
8. Rosenbloom A., Ferris R., Sipe D., Riddler S., Connolly N., Abe K., et al. In vitro and in vivo protein sampling by combined microdialysis and ultrafiltration. J Immunol Methods 309 (2006) 55-68
9. Whiteside T. Anti-tumor vaccines in head and neck cancer. In: Shin D. (Ed). Current Cancer Drug Targets Vol. 7 (2007), Betham Science Publishers
10. Whiteside T., Zhao Y., Tsukishiro T., Elder E., Gooding W., and Baar J. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res 9 (2003) 641-649
11. Altman J. Flow cytometry application of MHC tetramers. Methods Cell Biol 75 (2004) 433-452
12. Barnes E., Ward S., Kasprowicz V., Dusheiko G., Klenerman P., and Lucas M. Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells. Eur J Immunol 34 (2004) 1570-1577
13. Hoffmann T., Donnenberg V., Friebe-Hoffmann U., Meyer E., Rinaldo C., DeLeo A., et al. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex. Cytometry 41 (2000) 321-328
14. Schmielau J., Nalesnik M., and Finn O. Suppressed T-cell receptor zeta-chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 7 (2001) 933s-939s
15. Whiteside T. Down-regulation of zeta-chain expression in T cells: A biomarker of prognosis in cancer?. Cancer Immunol Immunother 53 (2004) 865-878
16. Markovic S., Nevala W., Uhl C., Celis E., and McKean D. A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood. Clin Exp Immunol 145 (2006) 438-447
17. Maecker H., and Maino V. Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry. Hum Immunol 65 (2004) 493-499
18. Miltenyi S., Muller W., Weichel W., and Radbruch A. High gradient magnetic cell separation with MACS. Cytometry 11 (1990) 231-238
19. Okamoto Y., and Nishida M. Dual-color ELISPOT assay for analyzing cytokine balance. Methods Mol Biol 302 (2005) 263-272
20. Carson R., and Vignali D. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J Immunol Methods 227 (1999) 41-52
21. Vignali D. Multiplexed particle-based flow cytometric assays. J Immunol Methods 243 (2000) 243-255
22. Elenkov I., Iezzoni D., Daly A., Harris A., and Chrousos G. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation 12 (2005) 255-269
23. Netea M., van der Meer J., Sutmuller R., Adema G., and Kullberg B. From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias. Antimicrob Agents and Chemother 49 (2005) 3991-3996
24. Whiteside T. Assays for cytokines. The Cytokine Handbook. 4th ed. (2003), Academic Press, New York, NY 1375-1396
25. Whiteside T. Cytokine assays. Biotechniques 10 Suppl 4-8 (2002) 2-5
26. Mitchell P. A perspective on protein microarrays. Nat Biotechnol 20 (2002) 225-229
27. Pavlickova P., Schneider E., and Hug H. Advances in recombinant antibody microarrays. Clin Chim Acta 343 (2004) 17-35
28. Weingarten P., Lutter P., Wattenberg A., Blueggel M., Bailey S., Klose J., et al. Application of proteomics and protein analysis for biomarker and target finding for immunotherapy. Methods Mol Med 109 (2005) 155-174
29. Tyers M., and Mann M. From genomics to proteomics. Nature 422 (2003) 193-197
30. Liu L., Chahroudi A., Silvestri G., Wernett M., Kaiser W., Safrit J., et al. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med 8 (2002) 185-189
31. Burkett M., Shafer-Weaver K., Strobl S., Baseler M., and Malyguine A. A novel flow cytometric assay for evaluating cell-mediated cytotoxicity. J Immunother 28 (2005) 396-402
32. Kern F., LiPira G., Gratama J., Manca F., and Roederer M. Measuring Ag-specific immune responses: Understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. Trends Immunol 26 (2005) 477-484
33. Taylor D. Past present and future of high content screening and the field of cellomics. Methods Mol Biol 356 (2006) 3-18
34. Calcagni E., and Elenkov I. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann NY Acad Sci 1069 (2006) 62-76
35. Whiteside T., Boyiadzis M., and Herberman R. Natural killer cells. In: Fink G. (Ed). Encyclopedia of Stress. 2nd ed. (2007), Elsevier (in press)
36. Whiteside T. Monitoring of immunologic therapies. In: Detrick B., Hamilton R., and Folds J. (Eds). Manual of Molecular and Clinical Laboratory Immunology. 7th ed. (2006), ASM Press 1171-1182
37. Ananworanich J., and Shearer W. Delayed-type hypersensitivity skin testing. In: Rose N., Hamilton R., and Detrick B. (Eds). Manual Clinical Laboratory Immunology. 6th ed. (2002), ASM Press, Washington, DC 212-219